XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Cancer Channel
subscribe to Cancer newsletter

Latest Research : Cancer

   DISCUSS   |   EMAIL   |   PRINT
Mutation Screening, a New Way to Manage Gastrointestinal Stromal Tumors
Aug 11, 2005, 00:49, Reviewed by: Dr.

Results suggested that mutation screening is likely to play an increasing role in the management of GIST patients treated with imatinib or other drugs currently in development.

 
Transgenomic Inc. announced today the publication of a study in which its WAVE System was utilized to detect mutations in the platelet-derived growth factor receptor alpha (PDGFRA) gene in gastrointestinal stromal tumors (GISTs). This study entailed analysis of the spectrum of mutations identified in a series of GISTs from more than 1,000 patients, coupled with assessment of the impact of various mutations on sensitivity/resistance to imatinib. Results suggested that mutation screening is likely to play an increasing role in the management of GIST patients treated with imatinib or other drugs currently in development.

Drs. Christopher Corless and Michael Heinrich (Department of Pathology; Division of Hematology and Oncology, Oregon Health & Science University Cancer Institute) and colleagues described this work in an article entitled "PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum, and In Vitro Sensitivity to Imatinib," which was published in the August 10 issue of the Journal of Clinical Oncology.

Dr. Corless commented on the significance of this work. "While the majority of activating mutations in GIST are found in a different gene -- the KIT gene, GISTs with mutations in PDGFRA represent a subset that poses new challenges in diagnosis and treatment. These tumors more often test weakly or negative for KIT protein expression, the current 'gold standard' for GIST diagnosis and initiation of imatinib therapy. In addition, based on our results, approximately two-thirds of GISTs are likely to be imatinib-resistant based on the presence of specific mutations, while the remaining third, harboring different mutations, are in fact likely to respond to standard therapy."

Collin D'Silva, Transgenomic's chairman and CEO, commented, "Important work by the team of Drs. Corless, Heinrich, and colleagues over the past several years has contributed enormously to advancing the 'bench-to-bedside' story associated with GIST. We believe their results to date strongly suggest that mutation screening of both the KIT and PDGFRA genes could be of significant benefit in the management of GIST patients. We are delighted to see our technology deployed so productively in their research, and we are optimistic about its potential positive impact on patient care."
 

- The work was described in an article entitled "PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum, and In Vitro Sensitivity to Imatinib," which was published in the August 10 issue of the Journal of Clinical Oncology.
 

www.transgenomic.com

 
Subscribe to Cancer Newsletter
E-mail Address:

 

About Transgenomic

Transgenomic is a global company that provides versatile and innovative products and services to the medical research and pharmaceutical markets. Transgenomic's WAVE Systems are specifically designed for use in genetic variation detection. They have broad applicability to genetic research and molecular diagnostics. The emerging pursuit of personalized medicine is driving the ongoing need to detect new, uncharacterized mutations and genetic polymorphisms. The high analytical sensitivity of the WAVE System makes it a uniquely enabling technology for the advancement of personalized medicine. To date there have been over one thousand systems installed in over 30 countries around the world. In addition to the sale of systems and consumables, Transgenomic provides services to pharmaceutical and biopharmaceutical companies in preclinical and clinical development of targeted therapeutics. For more information about the innovative genomics research tools developed and marketed by Transgenomic, please visit the company's Web site at www.transgenomic.com.

Forward-Looking Statement

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.


Related Cancer News

Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis
Breast cancer chemotherapy may deterioration in cognitive function
I-ELCAP study: Lung cancer can be detected early with annual low-dose CT screening
Genomic signatures to guide the use of chemotherapeutics
Elderly Breast Cancer Patients May Be Under-Diagnosed And Under-Treated
Listening to the sound of skin cancer
Tissue Geometry Plays Crucial Role in Breast Cell Invasion
Regulatory Approval for New Cotara(R) Brain Cancer Clinical Trial
CDK2/FOXO1 as drug target to Prevent Tumors
Key to lung cancer chemotherapy resistance revealed


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us